Neuro-oncology Practice
Overview
Neuro-oncology Practice is a scientific journal, published by Oxford University Press since 2014 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
Neurooncol Pract
Publisher
Oxford University Press
Start
2014
End
Continuing
Frequency
Quarterly
p-ISSN
2054-2577
e-ISSN
2054-2585
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 10631
29
SJR / Ranks: 5217
806
CiteScore / Ranks: 5214
4.90
Recent Articles
11.
12.
Sullivan J, Chandler J, Lesniak M, Tate M, Sonabend A, Kalapurakal J, et al.
Neurooncol Pract
. 2025 Feb;
12(1):45-50.
PMID: 39917756
Background: Report our institutional experience with pleomorphic xanthoastrocytoma (PXA) to contribute to limited data on optimal management. Methods: Patients with pathologically confirmed PXA treated at our institution between 1990 and...
13.
Zeremski V, Haage T, Mougiakakos D
Neurooncol Pract
. 2025 Feb;
12(1):168-172.
PMID: 39917755
Background: Despite recent significant advances, the treatment of elderly patients with primary central nervous system lymphoma (PCNSL) is still challenging due to comorbidities, poor baseline performance status (PS), and drug...
14.
Daun J, Capozzi L, Dhruva T, Urgoiti G, McDonough M, McLaughlin E, et al.
Neurooncol Pract
. 2025 Feb;
12(1):131-142.
PMID: 39917754
Background: To address the lack of access to supportive cancer care resources, the purpose of this study was to examine the feasibility of a tailored exercise program for neuro-oncology patients....
15.
Devaraja K, Avery J, Iyengar Y, Zhang Y, Climans S
Neurooncol Pract
. 2025 Feb;
12(1):143-152.
PMID: 39917753
Background: Primary central nervous system (CNS) tumors significantly affect individuals globally, with patients in Ontario, Canada, often bearing financial burdens for treatments such as oral chemotherapy due to insufficient coverage,...
16.
Garcia Fox R, Chukwueke U, Sannes T, Miran D, Chiu D, Bagley C, et al.
Neurooncol Pract
. 2025 Feb;
12(1):87-99.
PMID: 39917752
Background: Lower-grade (WHO grades 2-3) gliomas typically affect young and middle-aged adults and exhibit () mutations. For such patients, symptoms related to the tumor and associated treatment contribute to morbidity...
17.
King A, Roche K, Vera E, Pillai V, Polskin L, Acquaye-Mallory A, et al.
Neurooncol Pract
. 2025 Feb;
12(1):76-86.
PMID: 39917751
Background: This study explored differences in patient-reported outcomes (PROs) for patients with central nervous system (CNS) tumors during COVID, compared to pre-pandemic assessments, in light of impacted access to in-person...
18.
Patel M, Affronti M, Buckley E, Herndon Ii J, Mackowsky E, Johnson M, et al.
Neurooncol Pract
. 2025 Feb;
12(1):153-159.
PMID: 39917749
Background: Cancer treatment costs continue to rise with the development of new agents. Financial toxicity is defined as the quantifiable costs associated with cancer and cancer treatment in addition to...
19.
Reuvers M, Burgers V, Koekkoek J, Brandsma D, Compter A, Kouwenhoven M, et al.
Neurooncol Pract
. 2025 Feb;
12(1):113-121.
PMID: 39917748
Background: Low-grade gliomas (LGG) are among the most frequently occurring tumors in adolescent and young adult (AYA) patients (aged 18-39 years old at primary diagnosis). These tumors have a variable...
20.
Patel M, Serventi J, Dunbar E, Oliver K, Piil K, Seute T, et al.
Neurooncol Pract
. 2025 Jan;
12(Suppl 1):i26-i28.
PMID: 39776531
No abstract available.